-
| ISIN | US67080N1019 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NYSE |
| CurrencyCode | USD |
| Target Price | 11.5556 |
|---|---|
| Beta | 1.51 |
| Market Cap | 1B |
| PE Ratio | None |
| Dividend Yield | None |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NUVB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026